Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
2003 1
2004 1
2005 1
2006 2
2007 2
2008 5
2009 6
2010 5
2011 2
2012 2
2013 3
2014 3
2015 2
2016 6
2017 5
2018 2
2019 1
2020 4
2021 7
2022 3
2023 2
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

58 results

Results by year

Filters applied: . Clear all
Page 1
Epidemiology of multiple sclerosis.
Leray E, Moreau T, Fromont A, Edan G. Leray E, et al. Among authors: fromont a. Rev Neurol (Paris). 2016 Jan;172(1):3-13. doi: 10.1016/j.neurol.2015.10.006. Epub 2015 Dec 21. Rev Neurol (Paris). 2016. PMID: 26718593
Anti-Argonaute antibodies as a potential biomarker in NMOSD.
Carta S, Le Duy D, Rogemond V, Derache N, Chaumont H, Fromont A, Cabasson S, Boudot de la Motte M, Honnorat J, Marignier R. Carta S, et al. Among authors: fromont a. J Neurol Neurosurg Psychiatry. 2023 Sep;94(9):738-741. doi: 10.1136/jnnp-2022-330707. Epub 2023 Feb 21. J Neurol Neurosurg Psychiatry. 2023. PMID: 36810322
[Multiple sclerosis].
Fromont A, Moreau T. Fromont A, et al. Rev Prat. 2020 Apr;70(4):e125-e134. Rev Prat. 2020. PMID: 32877115 French. No abstract available.
High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS.
Jouvenot G, Courbon G, Lefort M, Rollot F, Casey R, Le Page E, Michel L, Edan G, de Seze J, Kremer L, Bigaut K, Vukusic S, Mathey G, Ciron J, Ruet A, Maillart E, Labauge P, Zephir H, Papeix C, Defer G, Lebrun-Frenay C, Moreau T, Laplaud DA, Berger E, Stankoff B, Clavelou P, Thouvenot E, Heinzlef O, Pelletier J, Al-Khedr A, Casez O, Bourre B, Cabre P, Wahab A, Magy L, Camdessanché JP, Doghri I, Moulin S, Ben-Nasr H, Labeyrie C, Hankiewicz K, Neau JP, Pottier C, Nifle C, Collongues N, Kerbrat A; OFSEP Investigators. Jouvenot G, et al. JAMA Neurol. 2024 May 1;81(5):490-498. doi: 10.1001/jamaneurol.2024.0395. JAMA Neurol. 2024. PMID: 38526462
[Multiple sclerosis].
Fromont A, Moreau T. Fromont A, et al. Rev Prat. 2013 Jun;63(6):851-9. Rev Prat. 2013. PMID: 23923767 Review. French. No abstract available.
DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France.
Sormani MP, Salvetti M, Labauge P, Schiavetti I, Zephir H, Carmisciano L, Bensa C, De Rossi N, Pelletier J, Cordioli C, Vukusic S, Moiola L, Kerschen P, Radaelli M, Théaudin M, Immovilli P, Casez O, Capobianco M, Ciron J, Trojano M, Stankoff B, Créange A, Tedeschi G, Clavelou P, Comi G, Thouvenot E, Battaglia MA, Moreau T, Patti F, De Sèze J, Louapre C; Musc-19; Covisep study groups. Sormani MP, et al. Ann Clin Transl Neurol. 2021 Aug;8(8):1738-1744. doi: 10.1002/acn3.51408. Epub 2021 Jul 7. Ann Clin Transl Neurol. 2021. PMID: 34240579 Free PMC article.
Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.
Cohen M, Maillart E, Tourbah A, De Sèze J, Vukusic S, Brassat D, Anne O, Wiertlewski S, Camu W, Courtois S, Ruet A, Debouverie M, Le Page E, Casez O, Heinzlef O, Stankoff B, Bourre B, Castelnovo G, Rico A, Berger E, Camdessanche JP, Defer G, Clavelou P, Al Khedr A, Zephir H, Fromont A, Papeix C, Brochet B, Pelletier J, Lebrun C; Club Francophone de la Sclérose en Plaques Investigators. Cohen M, et al. Among authors: fromont a. JAMA Neurol. 2014 Apr;71(4):436-41. doi: 10.1001/jamaneurol.2013.6240. JAMA Neurol. 2014. PMID: 24566807 Clinical Trial.
58 results